Is WST Stock Undervalued At $200?
1. West Pharmaceutical reported Q4 revenue of $749 million, beating estimates. 2. Stock fell 38% post-earnings due to lower-than-expected future guidance. 3. WST has underperformed, dropping 43% in 2024 compared to S&P 500's 28% rise. 4. Company's gross profit margin decreased by 150 basis points, affecting earnings. 5. Despite challenges, analysts see WST as undervalued at 5.1x revenue.